The National Comprehensive Cancer Network® (NCCN®) 2023 Annual Congress: Hematologic Malignancies™ is returning to San Francisco this week, marking its first time back since 2019. This live event will provide insights from world-renowned experts on evidence-based treatment for various blood cancers, as well as best practices for protecting vulnerable populations in the ever-evolving healthcare landscape.
The congress chair, Dr. Andrew D. Zelenetz from the Memorial Sloan Kettering Cancer Center, expressed that the program was designed to provide a comprehensive experience for the entire hematology and oncology team. It takes into account the latest advances, conversations, and controversies in blood cancer treatment. Attendees from around the world will have the opportunity to learn about the most up-to-date evidence and expert consensus for improving patient outcomes in the realm of hematologic malignancies. The event also offers networking opportunities and the chance to engage with leading experts in the field.
This year’s conference is a hybrid event, taking place in California for the first time in four years, with live online attendance options available via NCCN’s virtual platform. Session recordings will be accessible on-demand for 60 days following the event for all registrants.
The topics covered at this year’s congress include identifying and managing toxicities in patients receiving CAR T-cell therapy, revolutionizing hematologic cancer treatment with bispecific T-cell engagers, integrating new WHO/ICC classification systems, tackling inequities in access and quality of care for patients with multiple myeloma, managing graft-versus-host disease in transplant recipients, and prevention and management of blood clots. Additionally, speakers will share information and research on the treatment of various blood cancers, such as Adult Acute Lymphoblastic Leukemia (ALL), Acute Myeloid Leukemia (AML), Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL), and many others.
The NCCN 2023 Annual Congress aims to provide clear, understandable, and actionable updates to assist busy care providers in analyzing, evaluating, and contextualizing new clinical data. This will ultimately contribute to achieving the best possible outcomes for individuals with blood cancer in a rapidly evolving healthcare landscape.
Sources: National Comprehensive Cancer Network (NCCN)
